<SEC-DOCUMENT>0001193125-13-295775.txt : 20130719
<SEC-HEADER>0001193125-13-295775.hdr.sgml : 20130719
<ACCEPTANCE-DATETIME>20130719170308
ACCESSION NUMBER:		0001193125-13-295775
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20130719
DATE AS OF CHANGE:		20130719

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-187508
		FILM NUMBER:		13977535

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 430
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 430
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d568593d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Prospects Supplement No. 2</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(to Prospectus dated May&nbsp;30, 2013)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Filed pursuant to Rule 424 (b)(4)</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registration No. 333-187508</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>125,000 Shares of Series A Convertible Preferred Stock </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>12,500,000 Shares of Common Stock Underlying the Preferred Stock </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Warrants to Purchase up to 6,250,000 Shares of Common Stock and </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>6,250,000 Shares of Common Stock Underlying the Warrants </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g568593snap1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This prospectus supplement supplements the prospectus dated May&nbsp;30, 2013 (the &#147;Prospectus&#148;), as supplemented by that certain Prospectus Supplement No.&nbsp;1 dated July&nbsp;17, 2013
(&#147;Supplement No.&nbsp;1&#148;), which forms a part of our Registration Statement on Form&nbsp;S-1 (Registration No.&nbsp;333-187508). This prospectus supplement is being filed to update and supplement the information in the Prospectus and
Supplement No.&nbsp;1 with the information contained in our current reports on Form 8-K, each filed with the Securities and Exchange Commission (the &#147;Commission&#148;) on June&nbsp;18, 2013 and July&nbsp;1, 2013 (the &#147;Current
Reports&#148;). Accordingly, we have attached the Current Reports to this prospectus supplement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Prospectus, Supplement
No.&nbsp;1 and this prospectus supplement relate to the offer and sale of up to 125,000 shares of Series A Convertible Preferred Stock (&#147;Preferred Stock&#148;) which are convertible into 12,500,000 shares of Common Stock, warrants to purchase
up to 6,250,000 shares of our Common Stock and 6,250,000 shares of Common Stock underlying the warrants. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus
supplement should be read in conjunction with the Prospectus and Supplement No.&nbsp;1. This prospectus supplement updates and supplements the information in the Prospectus and Supplement No.&nbsp;1. If there is any inconsistency between the
information in the Prospectus, Supplement No.&nbsp;1 and this prospectus supplement, you should rely on the information in this prospectus supplement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our common stock is traded on the Nasdaq Global Market under the trading symbol &#147;ABIO.&#148; On July&nbsp;19, 2013, the last reported sale price of our common stock was $1.41 per share. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under
the heading &#147;Risk Factors&#148; beginning on page 5 of the Prospectus and beginning on page 23 of our quarterly report on Form 10-Q for the quarterly period ended March&nbsp;31, 2013 before you decide whether to invest in shares of our common
stock. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved
of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>The date of this prospectus supplement is July&nbsp;19, 2013 </B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>of the Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of Earliest Event Reported): June&nbsp;18, 2013 (June 13, 2013) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 430, Broomfield, CO 80021 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s Telephone Number, Including Area Code)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Bonuses, Base Salaries and Restoration of Severance </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;13, 2013, the Board of Directors (the &#147;<B>Board</B>&#148;) of ARCA biopharma, Inc. (the &#147;<B>Company</B>&#148;),
upon the recommendation of the Compensation Committee (the &#147;<B>Committee</B>&#148;) of the Board, approved cash bonuses (the &#147;<B>Bonuses</B>&#148;) for each of the executive officers of the Company in the amounts, set forth below, payable
on or around June&nbsp;28, 2013. The Board also approved, upon the recommendation of the Committee, the base salaries for the Company&#146;s &#147;named executive officers&#148; (as defined in Item&nbsp;402(a)(3) of Regulation S-K promulgated by the
Securities and Exchange Commission), in each case as set forth below. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:52pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Title</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Cash&nbsp;Bonus</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Base&nbsp;Salary</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael R. Bristow<BR>President and Chief Executive Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">272,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patrick M. Wheeler<BR>Chief Financial Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">265,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Christopher D. Ozeroff<BR>Senior Vice President, General Counsel</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">266,770</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board, upon the recommendation of the Committee, determined the Bonuses are to be paid in recognition
of the past efforts of each of the executives and, in the case of Dr.&nbsp;Bristow and Mr.&nbsp;Ozeroff, increased the salaries to levels that were in place prior to the executive officers&#146; voluntary salary reductions which were implemented to
save the Company&#146;s available capital. In the case of Mr.&nbsp;Wheeler, in addition to the increase of his salary to the level that was in place prior to the executive officers&#146; voluntary salary reductions which were implemented to save the
Company&#146;s available capital, his salary was increased by an additional $43,550. The new base salaries will become effective on June&nbsp;24, 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Board, upon the recommendation of the Committee, also approved the grant of severance packages for Dr.&nbsp;Bristow, Mr.&nbsp;Wheeler and Mr.&nbsp;Ozeroff which would require the Company to make
severance payments, in an amount equal to 6 months of their respective base salaries, to each of the foregoing executive officers of the Company in the event their employment is terminated under certain situations. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: June&nbsp;18, 2013 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Christoper D. Ozeroff</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Christopher D. Ozeroff</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title: Senior Vice President and General Counsel</FONT></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>of the Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): July&nbsp;1, 2013 (June 28, 2013) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 430, Broomfield, CO 80021 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;7 - Regulation FD </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;7.01 - Regulation FD Disclosure </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information in this report
furnished pursuant to Item&nbsp;7.01 shall not be deemed &#147;filed&#148; for the purposes of Section&nbsp;18 of the Securities and Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that
section. It may be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, only if such subsequent filing specifically references the information furnished pursuant to Item&nbsp;7.01 of this
report. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As previously disclosed, ARCA biopharma, Inc. (&#147;ARCA&#148;) closed its public offering of 125,000 shares of
Series A Convertible Preferred Stock (&#147;Preferred Stock&#148;) on June&nbsp;4, 2013. Each share of Preferred Stock is convertible into 100 shares of the Company&#146;s Common Stock at any time at the option of the holder; provided, that the
holder will be prohibited from converting to the extent that, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of the Company&#146;s Common Stock then
issued and outstanding. As a result of Preferred Stock conversions completed since the close of the financing, as of June&nbsp;28, 2013, ARCA had 10,096,162 shares of common stock outstanding and 55,894 shares of preferred stock outstanding.
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: July&nbsp;1, 2013 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Patrick Wheeler</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patrick Wheeler</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g568593snap1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g568593snap1.jpg
M_]C_X``02D9)1@`!``$`>`!X``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@,"
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`#H`K`,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/TN^)'Q(UKQ+K%]H7A^\N[#1;*=[#=9R"VGU&\MW`GD>Y4;
MT@,GR(D;?.J'KOP_\<>)OB?FV<9O5R?A_$.AD^%?L6X?%6K+F4Y.=.;>Z48Q
M5G3LM4ZDK_J'#G#6&H83ZWC8WKR]Y7^RN6ZBHN,F[_S)--OWK)1;XC3-$UC4
M6<&^OO.`+NAO+M'9$5FE7<)-N[&"<`?ZSA2,&3\LRO!9[FD*T:53&2=&=VIU
MJM^12E*,E:4DXV<I\SM92<H^XU-_15<5A*2C.4*4>:U)<L8J,DH<L=%%2LW&
M,>5*]U"ZN]=IO"FH?9K1Q=ZFPNWEBB\F]NI&>56"C:"<;<R':QR,-G!W?O?H
MGPMG*H8?$3Q6)ISQ=2=*,O:5W=\D7*SY[27OVYDY.HVH<G,I(X/[2P:E.G[*
ME+V,;OW5I=JT8^ZK;-VEK'5ZKEY^>O;/5+"=_LNH7^Z!E57BO+I62:,C#[26
MP6EX)`?@=3DE_G\2\ZRW%SBL;BZ5?!2YE+VU9J,W-3C+6<HN,II<R?-";CHW
M:[]&E+!8BE&U*G&%=.+BXP3:Y91<=$]>5VW3M*WVK/WCX._$K5-5OF\)^(YI
M+N[%NTVF:DX0R3"W4&:TN7B1%W)&%*.1N8Y#98Y;^CO!_P`2\QSK$2X=XCK*
MMF,E*>&JQA""=."TC/DDH0LH\D5&.KY%;F<I3^!XIX;CEU...PL7"C)1<H]-
M6X\R>^K2=I+9RE=Q44?1M?T.?#!0!\D?'']IJS^$GQ5^$WP^$5I/;^*]2#^,
MKF59'FT70KR3^SM+N+<H0D<[ZH\9(DR#$&P0=N_2$&].6]T[;WT3UMM96[M[
MV0:):OE7?M:UKK71WUZJU]M'];`@@%2"I`*D$$$$9!!';%1MY6"UM-K="CJC
M:FFFW[:-'93:LMI.VFPZC)-#827JQL;:.\EMT>6*W:4*':-68*20":%9;["_
M`_/SXN_M;_&GX"W^EZ;\2/A#X/G&L6=Q>:9K/AKQAJ4^DWWV'`O;1%O=(2:W
MOH]R/Y3ALI(K`_WK2A=Q5V^B3U[+2R>NMM-;6*46E>^D;7T:Z7=MU=6M:_GJ
MM_7]$\>_M7>(?#]CXGL/A/\`"NRMM2LK;4K'0]3\?:NNKW%G=1"XMRUY;:,]
MI:SO`\3;'R%,A!;Y?F?+3C=-M.-]-_396\GVT>MF@]V\;727Q75GIOHTN7RO
M?S2W,_X2?M>:#XW\=W7PD\>^%=4^&'Q/L[N?35T75+B"_P!*U74K0,]Q9Z7J
MD`7_`$@PA9HHY8U$T9S&['`:7&RNKV6^GW:]=%?IL[7$TXNV_;^ORLWI9Z=/
ML.H`^4OBO^U?X3\">*+;X;>"]%U/XJ?%._E^RV_@_P`+-&T=G=;!)Y6LZLP:
M&P*QDO(H$C1!3YH0X4W&-U=W25TK+JMTWLK=>J"UK=+\K2;M[K>_EIM?1W3O
M;=;-/VQ]?M4U&>Z^"?P_>8"6+P[<6?B3Q9>VBL,BWO\`5;:XMK9I5'\5NC`$
M\[MOSM>S35[^[NE9]+*[=M+ZZ6V2O9L=DE*.[5[/YZ+=I*W7WO1GCGQ(_:*_
M:;^!&H:2WQ)^&GP_\0^$=4U/3=+3QEX3U36K:RBEO+B&!EO(+Q9'TZYQ(Q6.
M9"CE"L<AP/,:C&2=K1Y;7U=EK;:S>G?3[VD)O2-ER[Z=;I)^2[V2W2OT;/T'
MM9EN;:WN$SLGACG3."0LR"55RH`(56`SCMSD\UG\N6W3^F_P;06LVKW2>C_+
M8L4@/DOPY^TS9:[^T[XI^!FS3XM'TC0XH=(U3>PN]1\7V*?;M=TW>93&T4%C
M(%15`<O;OQR-^G(^2]K<O77UMM962N[V?JMAVCIU_+:R:=FKZZZZI+1:OZTK
M,`H`_/S2-.CO=4N3+,8T_M"<,[(71'-Q(BAB4)0I\H.Q>2_0[OF_SFPV`IX_
M-:E*K5=-+$5)<R<H\KC.5..D(WDUS6DI)\RT;<5&W[MBJU2GAZ=364HQ@I1D
MTFHPIVM)M;V5K62;?PN<GS?0NF:9;:-8QZKJOD$6CHMG?VPA;^U%D&/[.\A5
M#2R%7PK-L^7).5`W_P!'Y)E>5Y)E%3-<TK4L-2HRIJA7Y;RQ7+."EAV[)?NK
M.SM3GRIQJKV/,W\-C,5BL37E@\/%NI64E5I<D4XV::G=I6YFK6B[<RN[25SJ
M["&SO[2&YCTLVUE9/=2V,HD1WLTO`,,\0C;<JHS!22"P^]NQBOJ,N66YQ@/K
MG]DU<!E^5SKO"S@E5I7<HS2J<_*XQIJ?)"*I+F=IS57W/:>75]MA*JI1Q*J5
M:\(JHI74M+_!O&\K*[;T3<5:[.$\5^&$MK8I%]EM+*8)-+?S92]U%R#D);A7
MD\LG!`#,"0Q)Q_K?@N.^$XPC6Q<^3"99BE>M*K%QJ8J;DI.4%:45%+DM!>UM
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M+RT^_P"[K^FGP^_Y$+P1_P!BCX:_],UE43^.7J_S"?QS_P`3_,_(OXJZ3>?$
MC]O&VTWP!#]ON='U[P9-K=]I[/)#IG_"/PQW&MW>H75NC):""(>3R48M*L9+
M%B&V@TH*Z5H[IW]([*U[)N*<GUTC+05[O>UE&S2L[))/?FNKV3TUOLT?HM^U
M3\5[SX/_``<U_P`1:1(L7B'4I;;PWX>D\S9);:GJ^^%;Z-`"SM;0K+*"OW7"
M-VPV,(IO711WV_6UWV76U@BDM]MEH][:7:V[W?:Q\X?\$]?AA86G@S6/C)JD
M2WWB?QKJE_:6.J70$]VFDV<Y2YNUN)%WBYU&_P#.DG<$%O+V\@DNYRUY?Y=+
M]TMM=I>J<ET3]VR;]U<NSZ]_1Z*UOQT;UV_1RLR3CO'W@?0_B-X0UWP5XBA\
MW2M=L9+2=E6-IK60X:WO+4RHPCNH)E21'QD,@]::T^0)VVT:V\M+?U^.AT&D
M:>-)TK3=+6XFNETVPM+!;FX*F>=;2".W668J`#(PC!)]2<Y/)&[MNUKB2MIV
M_K\#SSXU_$)/A;\,/%OC-56:_P!-TUH=$LR3OO\`7K]EL='LH54$O+)?3PX4
M#HI]*<%JM+J/3^ON&DW\.ZVTOZ:77]?<?DG\8_AMKO[-^M_`#XN&6[N/$-ZE
MMKGCJ[#S23WWCJ.Y_MG6HYIRO*W.GW]S:[3G)L^<@XDW3][EO;[+;V6JN_>O
M9/WMFN^FQ49:)J-N76RTOO:.FBTLK:II6/VG\/:Y9>)M#T?Q#ICB33=;TRQU
M2RDR"Q@OK=+B,,`,95'4$ACSGL`3SM<NG;^EJB;-:6Y=%IL^^JZ?GY*QLT@/
MA/PTX&HW!%K;SL;ZZW&="Z'%TYVN&VYY?/&[/?.X>;_G[PY5=/.:_LXT':I7
MTKNT/X[@X\R]Z*?,](>\K+6T9'[;CH0G@X3DY\W)%15-NZDX>ZK6E>TFF^=Z
MO[3NHOV7Q#97.L>&(HM(CL+N_P!+U"'4;ZPTBVE)-L\3VZQ/*Z&.:Z1I/-54
M))4-L!R#)^V\59?B<^X5HX7`T<-C\9D57ZU+#8*E5C+DE&$91G4G3A3K5JJ4
ME#XN9U+2Y'&*7Q^"K4\%F4I8KVE.C7BZ4957'>$I/W8N\J<+[N25E=N,HN2=
M'0?&=[)"-/M;._-]/$8!`L,@FA#C:S7'G0G@O@9<`*.JG`$OCY+QUF?U3ZAE
M.!KX?&XUPA'!+#U*:PD^:$)^WERJG4IPBG!<[C*'-*=53G>)W8[**7-+%U>5
M86C:49\R:E:/,E%IW51)QDUKS:<KNXN73^(I5MK"VM[IM);4+&V\N\@O_P#C
MYWEVV_9920DJ*HX`/.,#<>7^PXN=*EE\,#5^J?7J%%TJE*M3:J^W4+3AA9WJ
M0G&$*CM**C;V46^>:FWX^6I3JU:L%44)2C.'(TX*%_=]KJI1=UL^9N]F[-,\
MH\!2[OB=HX>!8&$=[A%1T0$IC]V3D^4%*@`L<D9YP=_Y/X957+Q.R=QI?5X*
M.)A>F[/3#2BO<E.-H54DGR74(RLH6^+Z7/8<G#U:-W)M1?3E5FK:\K3=K[:R
M?O<ST:^Q:_M4_)SY%_;`\3ZRO@G0?A)X/D7_`(33XUZ]!X+TV(2M$\&BL!/X
MBOY7B5I(+5+$+%)*`,)</MY&*N$;W:=N7[K;:OHE=;:WL./NO716>NOW:>5^
M_:SN,O/`_P`>[GX?2_"\>%_@E%X2;PLOA6.U34_%68K"*R%G$X1M.V/<91)2
M64J6^8_,"9&Y153FBGR13TW;?V4FW:-DK:I_$FI>ZTU'1;^]ITT5K7;MJ[MM
MKHK6:=[GRA^P/XHU'X>?$WXC_`;Q3<O#>O//<6-O*V4'B#PX?LFJP0%CPLVG
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M-3TW]A'Q7\,/$7PUEL/"_A[2?#WCK2?+@\?QQ`W&J:]<2JKP>([C4;HO<ZA:
M7RN)#YDCB.4R*0"1E5'*]_AY7:VBM:^EDEYO1+5O1-DOLW>^KWMV2N[W25K7
M;LGZE#_@HEHMWJ'P8T348`?LVA^-M)N+YE#%HH+F&YMDD^4$J!*57)&,NH)Y
M&2DU%O=-)VMIT:6J:V;7ROZ-Q6CC;2Z?W='\G]^G73T+]AW5[/4_V<O!=O:R
MH\FB2ZKHMZB;1Y-Y:7\LDB$`#JLZ."0,[_:IG?FO??9::):):);)?Y)*R2:Y
M;:6MH^UUVU?2U_/H?7-0(*`"@#X3^/=[XG^*7QO^'GPC\`0:+J4GPT,7Q8\9
MP:]<7<&A&Z@/V7POI>K/8PRR9::?[1&JHWS,"XVIAM(-0T<^5M<RCLVHM+35
M.R;5VKVT=BTN6*<HOE;2=[VM;II:[5[-O;FM9VOC_M)^`?CW\3OA-KEEXK\.
M_"U8/#F_Q9;2Z!J'B*ZUV&318Y;J2+34O;,0;Y;,2PMEE++D9YY<6DVH/E;5
MEI=7M;LFKINWFTM-THI1E'5RC=72]U[Z*VJNMKZ]U?9Z/_!/SXDMXK^$,W@N
M^N#)JGP[U`V$"RDBX/A[5`]]H[2J<X:-C=P'YO\`EDHQ@!G=6*3]U62TOTZZ
MI]5=-+?1:N][)W7;2W9->JW;ZMVZV[7^\ZQ$?GM>6MWX>\0ZIIU]$ZSVFI7"
M7$+QX@97<R12VY(*_O(&^4DN""YY#'?_`)UY]E6,X:XBQ.5YHZ<<71JRFZ47
M>%2G.?-&46KJ/-:UI.>[LVVV_P!WR^O1S#+X5\,^6,HQ7*W:7P-.R:DY0B[)
MOH^6]UH_4/#OB\1"V*;[?3;!S<-;1/L$]ZJA$%RXS)(&D4';N"C[H4[LO^@<
M-<9.A3H8:K5J0P.`M4C3M&<JF)3]V+J:3E&4H^S_`'DKQ]U*48^['P,PRF3]
MK.,.:I4YH2G-ZJG=-R5].9[\R5W\&RO+L!X^1+;3Y)9EF:XGOX]3*11K+);7
M&$5E(C)8(I8#.23'SN4GS/O%XCTZF#P>*Q-6,JF-K8E8E4:<*4JGM(PIJ*DM
M5-0G;DNE:%DG[\9^+#(I.52DN:G"E3@Z;G>:7)S2BW'K%M<KDDTKWE=VMYIK
M_BDSQM:W<DLQ@5H[2XV_O(HP3M@D8QDS#9*'42?<)4]"/,_*N(.*<1B(U<%B
M.6K/"2<,+5Y5#V&'3ERPDX6C6:IN+BVG&*E:4JFI]+@<M>':K>SY>?2</>3;
ME'EORJ-XZMJ;WD[.-]IR_"&"^U7Q]:WD0DDATNVN9;R<J^(Q(HA5"X79F1F!
MP6!8?,!S^\]7P;RW,<=QQ@<SP]*=;`9?&K*M54?<BYPE%WFT^9W:=TXIM**;
MD[2RXMK8?#Y14P[J1=2IR*,?>NG=V6J7O65_M*RNFEJ?5?BCQAX7\$::=8\6
M:[IOA_3%?RQ=ZE<I;QO*$:011`_--,41B$C5F.,`$D`_VREV7]>;V7;7K9;M
M'Y#;\/\`A_R3?HF]DS\W_A[\<?`'Q,_:WU_X@>)M<30O"OA+P>_AGX4OXC@G
MTZSU&>>ZC77-4MWO8%CM[B<L[1!W60H0!@L`UVT:3U6W3U>MNUN[6EM#2TE"
M*V=]$E;=/FN]5IHGK:RU2LS].9;ZSMK*349[F&"PAMC>27<LBQV\=JL?FM.\
MC$!8Q'\VX]JBSO;JNAG:WR[>7H?B-^T'XQ\+^#?VK='^*_PIU2V\4A)-&\3:
M^FA++>VQU:VW6>I68O[>&6*62\T?<VQ25###?ZQA)JFI149K2%K)M.-NZ7-\
M2?*TE;6+;6ERE&46XV>^VVW2Z5[;ZZZ-6?1?K#\._CU\+?B;HBZQX;\5:?OA
MTIM7U72;Z7[#K&AVD*;KI]5L+@)):QP'AI2/+Y7#?.N<W%I7W2[;_=O^'H)I
MJ7+;;;\>JNEHN^A^8O\`P4!^)'@WXE:MX!T7P%JZ>+9_#UGKEWJT^@Q37VGP
M#4HH8K2T&H0P/"]TZQ^8%1F`5T)/S;6TBG'32ZVUC;>*ZW73I9VWO%-%Q34'
M[OGYV2DMEJOG=:Z)-IO]'_@M\6?AA\1O!7A?P_H'B72M4U*/PEIMAJ?AJX8P
MZO;BRTJWLM3MKW2KJ-)=D;+)'(=A0@\$@BIFFI2>C46]5MN2[WY[6N[]/757
M=EZZ=+NY^9GQ'\,^*/V+/VAM-\:^#;:Z?P%XCO+BXTZS@CDGM[_1;NY$^M>"
MKF.-`%NK65S-9,6#8=<<GY[YKQV48Z)M*W?IHEWVL^6-]=6))*-O>E:22=WL
MDM[;WE=.SM?J]#])-+^(_P`$OVF/!%]X0M=<L[^'Q=HUU;7GAG48WT_Q'8,(
M\R.VEWT:2+=V-QY<BR()(]\:$,RM@YJ+CJK22W5^G6ZW79_@]F)J45_+I:_3
M73TOY/75=SX>^'MQ\1_V%/'&JZ)XZTC5O%?P6\67@G_X2OP_97%_%I5W&3%#
MJK64,)>UNS;[%O+9FPYQ)%_#NMMS791VVNM4EU;:V2NV^6SLK6'R]5OI=]+7
M=KI;/K>V^FJ:9^D_AOXO?"_Q;I5OK/A_Q[X5OK"Y1'1_[;L+>9"ZJPCGM;F>
M.:WE&X`I(BD'C%9N,HMJS3B*S6EMNVOIL?.GQ^_;$\#_``ZT+5='\`WD?CWX
MA3V]S:6%AX;#ZK8:+<M&T:W^L7]BDL4:PNR,D*&1Y&VC`!^:H0NTKJ-]KWWZ
M7LFUV[_F-)12E+X5NEO;\OE=/T-CP7\1_"'P`^`_@V7XD>*FF\2W'AH>);JP
MNIKJ\\1Z]JVMM-JDL5G8NLET?,NK@0KN39'A03MQER3E+2]E\W9:OM>W>VRZ
M6T'?2^BC9;^=M$VM.R6VV^K\A_8L^(/A#Q+J_P`3?&?B;6[2P^*OQ/\`&\TJ
MZ#JSFSU6/PY8Q8\/:7ID5PB?;+>.U=BWDF3YU)8DY9B>MN7:.MKZ+17TT6EK
M;76UWNQ*5K;**6FB>E[/N]->[O?J??7B37?#OAS2;B_\4ZGIVDZ*V+2YNM5G
MBMK(_:5:,02R3$+^\&Y0I/S=.]1%._N[QU^[_(E:?]N_UU^ZW7;J?B%\&OBS
MX9^`'[2?C#4-(N]0U3X0:EK&MZ#<:CI6G7]Q9G0[J]^VZ/K4*I;'SX+"\8H0
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MUM<98;0&88^5AU&TXWL/FY+Z_P#$O&`Y>3_6W'<L6W'_`&7#Z.T4KWD^9^[[
M^W/HO=2LU_KSB+W67THM\MY<SOHM5LE:[;CU7<B_X9]TUI!++XGU1CG#[+2T
M0NH=F^^/F5BK$9YQG@YR2Z7T=\H4Z-3$<18NI.C+7EHTX*<%*ZB^62<>:.DN
M6S3E)*323$^.L6HS4,'3BY)*+<G:.FKMR^\[V:;=E9Z+F=O7_"OA#1/!M@VG
MZ);M"DKK+<S2R-+<74R($$L\C?>;:,```#L*_9N&.$\EX1P,\!DN&^KTJLE.
MH[N4IS2MJY-OEC=\D6WRIV3L?*9AF6*S*LJN)GS.-U&*5E&/9=79)*[NW;74
MUM1T?2=8CBAU?2].U2*"43P1:C96U]'#.H(6:)+F)Q'*`2`Z@$9ZU]*M'=:-
M:7\NJ_`X$VMM/ZL<[!:^`O$,MSIL.G^&M8?2FC6XM_[,L+R&S=]P1,M;M$DF
M`WRJ<@=0`1FGSQWO'YCY7&*>RT6Z_P`25E]]CI;QM.M-/N/MYLX-,BMFCN1=
M>2EDEH4\IXYEEQ'Y!C.PHPVD';CG%2KW5M^@KVUO:QFV/AOPM:VZKIF@>'[>
MTFC1T6QTK3HK>6)EW1LHMX`CQE6!!&1@\<&C6+>\7L^CLMD_1WTZ"72W3;_@
M$D7AGPW!-<W,/A_1(;B\MY;2\GBTJPCFNK6<$36US*EN&GMY`2&C<LK9Y!I\
MSVN[+I<?Z67R5[?==V[78MIX9\.6$?E6/A_1+*+.?*M-*L+:/(&`=D,"C(!(
MZ4<TE]IKYL'^(0:!X<TZ[DU>VT71;"^6*19=3@TVQM;L0-\\RR7L<*R"(X+,
M"^.,FB\G[MVUT6N_H&WEM^%TON3=NUV0VUQX9\6VXN+<:5K]I9W3QQSM!!?6
M\%W&H$GD2RQL@E5'4%HSG##G!H:E"WV;]G_D/WH?W;/\5I_FK^OF6H=`T*WO
MQJD&BZ3!J:QM$NHPZ;9QWZQ.-KQB[2$2B-E`!4/@@<BE?\-/EII^"^Y=A7>U
M]-[>>O\`F_O?<TIH(;F*2WN(8IX)5*2P31I+%(AX*21N"KJ>X((I-*S5M'HU
MY;!MY6/,M0^"/P?U2Z>]OOAIX*GNI.)9O^$>TV)I<G)\T0VZ"7)Y.X'))SU-
M5S-:=O)#3<;I.UU9^GZ?(Z[1_!WA+P[$(="\,>']'C")&5TW1["RWK&,*)&M
M[=6E(Y.7+$DDDY)-#;;NW?6_SUU\MVOF2E;RMI\OZ1?NM"T2]NDOKW1]*N[V
M*/R8[RZT^TN+J.'YOW27$L+2)'\S?*&`^8\<TDVMFU8?;^[MY==.VNI'_P`(
MYX>%Y!J/]A:,-0M&W6M]_9=D+RV;#+N@N?(\R%MK,,HPX8CO3YI:ZO7?4-M-
MDNGSO^>OJ6M0TO3-5M6L=4TZPU*R9UD>SU"SM[RU:1'WK(UO<1O&75_F#%<@
M\]:2;6S::!>[M[K6UM"NGA_08HOL\6B:1'!@KY":;9I%M8;67RUA"X*\$8Z<
M4;1<-HN]X]-;WNMM;N_>[N';^[MY?Y&:?`_@ICEO!_A9CR<GP_I)/))/)M/4
MD_C3YI+JU;S#]-CJ:D`H`*`"@`H`S-9U2UT/2M0U>\=4M=-M)[N9F.T;8$+!
M=P4[2S`*#@X+4TKM):`NGY+?Y+37L>$?#37WT6/18[K0KEI?B+J^IZI-KN^&
MWB-XY>:&U2SV>9-;PV:J//`C7<S`;\[VUE&ZW^!*_:^KTUNO3[KLOXNMHI2Y
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M5;6^3Z/=/JCRV_\`B9KUKXB\6:Q:Z?/=>!O!-O;Z7K-I)]GL=0&LS3Q&ZN+;
MS(I'NQ;PO%^Z$D8*L3D%@'KEBDDVDW9+M?IVU=TM]7:ROO27NJRL]=]VTM$K
M;*UGO=\VSLD>F>+?$MKHW@G5O$JE7@31GNK59,*)7NX%6S5E96X9YHMPVMQG
M@XJ4DI)25TFDU:_6VO9=&WHEJ]"5HU9V:VVWZ;NUOT[GF?@#75\':7\/O"IT
M&X6V\3+<A=7618C<:U)'_:-]+_9SQ^<+%5D8+.Y`*HOIE[FHWO>UDMD[+9)-
MVLG)O17OO:]M!)VMJW'5=N7>_>VMUHNF[EI[+JNMVFDM:6\BS7%]?R&*QL+5
M/,N;AEQOD*](;:/*F29R%4$=6(4Q&#E>VBCNPM:WV5LK[7Z*^R?K9>9@>%/%
M\_B;_A(+C^R);+3]&U";3;><3?:I-1N+)#]O-M'#%B2..8>6C(S;ST%5*"CR
MJ^K[Z+M\OZVV*M%)6>MW?JDNE[7L_)<VFM]K\S'\4Y[V_P!?TW1?"6J:Q>Z%
M+:J;:WN((I)8;A/,::9G0BUD5&0?9R'?<""<G`;I\J6MMM]%\O37I9^0*.CZ
M*-[/HVG9)-V5M+MWOVB['2>,O&T?@[0FU>;3+FZE6"*9[176);<RLD82:X92
MN\2OL"(&9RA"CD9E15TF[*]DUU]%IT5_):[)B2=[:*U]W9:6NN;5+=6>VW=7
MY[_A:>=>MM"3PWJ`EOM`.NV)>>.*9XQ@XO8'C!TJW6,.QGN"`1C"\@-2IKI)
M.S2TZ/LU>ZW7^016C;]U1UO=/3WMN[;CHK[7=]K]EX,\2-XL\/66NG3YM,^U
MF91;3.)<B"9X3-#*$42P.R,48#!'<]:B2479?9\K=+_/U7YBTZ:+Y?I_DO2V
MKYWQ!\1[?2X(I=(TJ?73=ZS:>'].>*XBMK>_U2YE,+)9NZN]Y;6[*?-FA1T&
MT@-T):A:Z?NN*3LTUH_.UMNF^RMJ."3MK97:[;+OLK]_)V3=D_25W;1N`5L#
M<JDLH;'(#%5)`/<J/H*C;RL(=0`4`%`!0`4`%`'G'Q/T'6?$?AV#3-(MTO(S
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M2WIHM7N]--6I<L;)N-Y*ZUVVW2?+;KIJN]DANB:;_P`*U\(>(=>UVZ@O=9N7
MO_$OB&]C!C@GU"1,QVT)<AOLT0$4$9.&(R<9:I;YFE\,4[+=Z7M?17VM?32V
MNBN)\JD[/1;-VO9+3MVTVU>MC@/#/@OQ'KG@VS\/:K9?V9:>)M5_X2GQEJ_V
MF"2;5;>]O!J(TJRA4>;$TL<=O"[SKB)$R/,WY;23@F^KBE9:-73[WZ::I+[[
ME77O->[>ZLV^9.R[Q7I*]F_>=Y7/2_'/A6]\2Q^&-$M88/\`A';35HK_`%Z%
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M/"^I>*?$N@PW\5NW@W1`VKW%L]R0^K:Y'N33X)[94(^Q6^3(WF;@Q8@#CYJA
M)0B[.TWMH[KY_COO:ZL-/EV;U5FK*R5]59I\UTEV26EW=VX&\\">-6T3Q#?"
M*VN/%_C74[:SU=H=0@MXM'\'PR+$NCV-S+$1L^R*1((P0PD.%+#YB]/G3Y5'
MEZVUUM=MI7>R^26]D4W&*]VRY;6T:OTTOLDMDN75WNY+F??^(=`\0)\/[KP_
MX=-E'J:V45C:P6I_LZU%FI2*:TMY7W&$M;!U\U^<NQ.3P4I)2O:UOS[DW497
M5Y)7T=NS25MK+3[NFRY2Q\(>+Y/&.@ZA>6.D6&@>']$@BT2RANDNK70[V>..
M'45BM!!&UYJ!A1@MVVQ09#M)"@M?M$HRZN735=;;KHHWLMNFFX*ROK=+=]7;
M76][7=KV:NHZZV/<:P$%`!0`4`%`!0`4`%`!0`4`%`'AOQ^FEB\%+''+)&DV
MI:?',B.R+*GV^S^215(#IR>&R.:UI+5^2_1FM%)R::NN5Z?<>UVH`MK8`8`@
JA``X``C7``J):2ETLV81^&/HOR)ZDH*`"@`H`*`"@`H`*`"@`H`*`/_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
